Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.
Subscribe to Eagle’s Eye View
Pas encore de commentaire